Published in J Urol on June 20, 2013
Renal mass biopsy: "just do it". J Urol (2013) 0.83
Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways. Oncotarget (2015) 0.77
Evaluation of p27 Expression in Salivary Gland Neoplasms; A Step Forward in Unveiling the Role of p27. J Clin Diagn Res (2016) 0.75
CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma. BMC Cancer (2015) 0.75
BAP1 loss defines a new class of renal cell carcinoma. Nat Genet (2012) 4.97
Epidemiology and risk factors of urothelial bladder cancer. Eur Urol (2012) 4.45
Single-incision, umbilical laparoscopic versus conventional laparoscopic nephrectomy: a comparison of perioperative outcomes and short-term measures of convalescence. Eur Urol (2008) 4.09
Systematic review of complications of prostate biopsy. Eur Urol (2013) 3.66
Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res (2002) 3.54
Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. J Urol (2013) 3.35
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol (2009) 3.14
Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer (2009) 3.12
Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol (2011) 3.12
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol (2009) 2.99
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell (2013) 2.94
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol (2013) 2.87
Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer. Eur Urol (2009) 2.76
Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer (2010) 2.75
The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol (2011) 2.72
Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol (2007) 2.66
Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol (2009) 2.55
Cost-effectiveness of medical expulsive therapy using alpha-blockers for the treatment of distal ureteral stones. Eur Urol (2007) 2.52
Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol (2006) 2.51
The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol (2011) 2.43
Flexible ureterorenoscopy versus extracorporeal shock wave lithotripsy for treatment of lower pole stones of 10-20 mm. BJU Int (2012) 2.32
Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol (2011) 2.31
Laboratory and clinical development of single keyhole umbilical nephrectomy. Urology (2007) 2.28
A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. BJU Int (2007) 2.25
Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma. J Urol (2013) 2.22
Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol (2008) 2.20
Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology (2009) 2.17
Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol (2012) 2.17
Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol (2010) 2.11
Climate-related increase in the prevalence of urolithiasis in the United States. Proc Natl Acad Sci U S A (2008) 2.09
Perioperative outcomes in patients undergoing conventional laparoscopic versus laparoendoscopic single-site pyeloplasty. Urology (2009) 1.96
Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol (2009) 1.92
Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol (2009) 1.90
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res (2008) 1.90
Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol (2006) 1.86
Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res (2006) 1.84
A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med (2012) 1.84
Cost comparison of robotic, laparoscopic, and open partial nephrectomy. J Endourol (2011) 1.83
Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol (2010) 1.83
Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J Infect Dis (2004) 1.83
Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol (2006) 1.82
Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int (2011) 1.78
The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur Urol (2009) 1.78
Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75
Semirigid ureteroscopy for ureteral stones: a multivariate analysis of unfavorable results. J Urol (2009) 1.74
Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. Eur Urol (2013) 1.67
Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol (2009) 1.66
Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol (2012) 1.65
Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey. Urol Oncol (2008) 1.64
Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol (2011) 1.62
Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int (2010) 1.61
Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol (2010) 1.61
Cost-effectiveness of standard vs intensive antibiotic regimens for transrectal ultrasonography (TRUS)-guided prostate biopsy prophylaxis. BJU Int (2011) 1.60
Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A (2012) 1.60
Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. BJU Int (2008) 1.60
Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol (2006) 1.60
Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol (2011) 1.59
Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol (2010) 1.57
Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Eur Urol (2012) 1.57
Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol (2010) 1.57
Deep lateral transurethral incisions for recurrent bladder neck contracture: promising 5-year experience using a standardized approach. Urology (2013) 1.56
Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol (2008) 1.54
Radiation exposure in the acute and short-term management of urolithiasis at 2 academic centers. J Urol (2008) 1.53
Tissue microarray constructs to predict a response to chemoradiation in rectal cancer. Dig Liver Dis (2010) 1.53
Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU Int (2013) 1.53
The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma. J Endourol (2011) 1.53
Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer (2010) 1.53
Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol (2009) 1.52
Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J Urol (2007) 1.52
Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU Int (2011) 1.50
Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology (2008) 1.50
Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. BJU Int (2007) 1.50
ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol (2012) 1.49
Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. BJU Int (2014) 1.49